Therapeutic vaccination in the immunotolerant phase of children with chronic hepatitis B infection

Pediatric Infectious Disease Journal

Volumn 22, Issue 4, 2003, Pages 345-349

  Dikici, Bunyamin ^a   Kalayci, Ayhan Gazi ^b   Ozgenc, Funda ^c   Bosnak, Mehmet ^a   Davutoglu, Mehmet ^a   Ece, Aydin ^a   Ozkan, Tanju ^d   Ozeke, Turgut ^d   Yagci, Rasit Vural ^c   Haspolat, Kenan ^a  

^a DICLE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b ONDOKUZ MAYIS UNIVERSITY   (Turkey)

^c EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^d ULUDAG UNIVERSITY   (Turkey)

Author keywords

Children; Chronic infection; Hepatitis B virus; Immunotolerance; Therapy; Vaccine

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ACTIVE IMMUNIZATION; ADOLESCENT; ARTICLE; CHILD; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; IMMUNOLOGICAL TOLERANCE; INFECTION PREVENTION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SEROLOGY; SERUM; STANDARDIZATION; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VACCINATION; VIROLOGY; VIRUS LOAD;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOCOMPETENCE; IMMUNOTHERAPY, ACTIVE; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MALE; PROBABILITY; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; TURKEY;

EID: 0344080577     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200304000-00011     Document Type: Article

References (21)

1. Lebray P, Pichard AV, Michel ML, et al. Immunomodulatory drugs and therapeutic vaccine in chronic hepatitis B infection. Presented at the EASL 2002 International Consensus Conference on Hepatitis B, Geneva, September 12 to 14, 2002. Available at: http://www.easl.ch/hbv2002/abstracts/4.1745. doc.
2. Couillin I, Pol S, Mancini M, et al. Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. J Infect Dis 1999;180:15-26.
3. Mahoney FJ. Update on diagnosis, management, and prevention of hepatitis B virus infection. Clin Microbiol Rev 1999;12:351-66.
4. Chisari FV. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995;13:29-60.
5. Boni C, Bertoletti A, Penna A, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998;102:968-75.
6. Michel ML, Pol S, Brechot C, Tiollais P. Immunotherapy of chronic hepatitis B by anti HBV vaccine: from present to future. Vaccine 2001;19:2395-9.
7. Lok ASF, Wu PC, Lai CL, et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992;102:2091-7.
8. Lai CL, Lok AS, Lin HJ, Wu PC, Yeoh EK, Yeung CY. Placebo-controlled trial of recombinant alpha 2-interferon in Chinese HBsAg carrier children. Lancet 1987;2:877-80.
9. Dikici B, Bosnak M, Kara IH, et al. Lamivudine and interferon-alpha combination treatment of childhood patients with chronic hepatitis B infection. Pediatr Infect Dis J 2001;20:988-92.
10. Dikici B, Bosnak M, Bosnak V, et al. Combination therapy for children with chronic hepatitis B virus infection. J Gastroenterol Hepatol 2002;17:1087-91.
11. Braden GL, Treatment of hepatitis B. Available at: http://www.medscape.com/viewarticle/434534.
12. Lok ASF, Chung HT, Liu VWS et al. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology 1993;105:1833-8.
13. Wai CT, Lok AS. Treatment of hepatitis B. J Gastroenterol 2002;37:771-8.
14. Vitiello A, Ishioka G, Grey HM, et al. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection: I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest 1995;95:341-9.
15. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccines. Annu Rev Immunol 1997;15:617-48.
16. Jung M, Spengler U, Schraut W, et al. Hepatitis B virus antigen- specific T-cell activation in patients with acute and chronic hepatitis B. J. Hepatol 1991;13:310-7.
17. Pol S, Nalpas B, Driss F, et al. Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J Hepatol 2001;34:917-21.
18. Boni C, Penna A, Ogg GS, et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 2001;33:963-71.
19. Sokal EM, Conjeevaram HS, Roberts EA, et al. Interferon alpha therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology 1998;114:988-95.
20. De Maria N, Idilman R, Colantoni A, Van Thiel DH. Increased effective immunogenicity to high-dose and short-interval hepatitis B virus vaccination in individuals with chronic hepatitis without cirrhosis. J Viral Hepatol 2001;8:372-6.
21. Mahoney FJ. Update on diagnosis, management, and prevention of hepatitis B virus infection. Clin Microbiol Rev 1999;12:351-66.